Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diversity of Antigen Receptors01:28

Diversity of Antigen Receptors

1.8K
Antigen receptors are essential components of the immune system crucial in defending the body against foreign invaders. These receptors are present on the surface of B and T cells, enabling them to recognize antigens and mount an appropriate immune response.
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel and accurate EEG emotion classification model based on multiple attention local binary patterns.

BMC medicine·2026
Same author

CD38<sup>hi</sup>CD19<sup>dim</sup> cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade.

Frontiers in oncology·2026
Same author

Nanomedicine Meets Immunotherapy: Advancing Adoptive Cell Therapy with Nanoparticles in the Treatment of Cancer with Sustainability Perspectives.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

A cell line development vector strategy for improved expression of a trispecific T-cell engager in CHO.

mAbs·2026
Same author

Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity.

Nature cancer·2026
Same author

Improving dual targeting selectivity in T-cell engagers via synapse-gated and affinity-tuned trispecific antibody design.

mAbs·2025

Related Experiment Video

Updated: Feb 23, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K

A TCR-based Chimeric Antigen Receptor.

Even Walseng1, Hakan Köksal2, Ibrahim M Sektioglu2

  • 1Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.

Scientific Reports
|September 8, 2017
PubMed
Summary

Researchers developed a novel TCR-CAR therapy combining T-cell receptor (TCR) specificity with chimeric antigen receptor (CAR) signaling. This innovation allows natural killer (NK) cells to target cancer cells, enhancing immunotherapy options.

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.4K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.5K

Related Experiment Videos

Last Updated: Feb 23, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.2K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.4K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.5K

Area of Science:

  • Immunology
  • Biotechnology
  • Cancer Research

Background:

  • Engineered T cells, using Chimeric Antigen Receptors (CARs) or T-cell Receptor (TCR) redirection, show promise in cancer therapy.
  • CARs target membrane antigens, while TCRs can target intracellular antigens but require T-cell specific signaling machinery.
  • Existing TCR therapies face challenges like signaling protein competition and unpredictable specificity due to mixed dimer formation.

Purpose of the Study:

  • To engineer a novel therapeutic construct, TCR-CAR, by fusing a soluble TCR to a CAR-signaling domain.
  • To assess the specificity and functionality of the TCR-CAR construct.
  • To evaluate the applicability of TCR-CAR redirection beyond T cells, specifically in NK cells.

Main Methods:

  • A soluble TCR construct was fused to a CAR-signaling tail to create the TCR-CAR.
  • The TCR-CAR construct was expressed and its specificity and functionality were analyzed.
  • The NK cell line NK-92 was transduced with TCR-CAR and its reactivity against pMHC targets was assessed.

Main Results:

  • The expressed TCR-CAR maintained the specificity and functionality of the original TCR.
  • TCR-CAR redirection was successfully demonstrated in NK cells (NK-92 cell line).
  • Transduced NK cells exhibited reactivity against pMHC targets, indicating successful redirection.

Conclusions:

  • TCR-CAR represents a novel approach to overcome limitations of traditional TCR-based therapies.
  • This technology enables non-T cells, like NK cells, to utilize TCR-mediated targeting.
  • TCR-CAR therapy offers a promising strategy for cancer treatment by combining NK cell cytotoxicity with broad TCR target recognition.